|
Boston Scientific Gets FDA Approval For Promus Premier Everolimus-EPCCS …
NASDAQ (RTTNews.com) – Boston Scientific Corp. ( BSX ) said Monday that it has received U.S. Food and Drug Administration or FDA approval for the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, the company’s next-generation … Boston Scientific Receives FDA Approval For Promus Premier(TM) Everolimus …Wall Street Journal FDA approves next-generation EESHealio BSX scores FDA device approval for drug-eluting stent for coronary artery …MedCity News Worcester Business Journal all 10 news articles » |
Cardiac Biomarker ST2 Proves Valuable In Helping Risk Assess Heart Failure … – PharmiWeb.com (press release)
|
Cardiac Biomarker ST2 Proves Valuable In Helping Risk Assess Heart Failure …
PharmiWeb.com (press release) Given that over 80% of heart failure patients are 65 years of age or older1 it’s no wonder then that according to the American Heart Association the number of Americans with heart failure is expected to jump from just over 5 million today to 8 million … |
Boston Scientific Receives FDA Approval For Promus Premier(TM) Everolimus … – Wall Street Journal
Boston Scientific Receives FDA Approval For Promus Premier(TM) Everolimus …Wall Street JournalNATICK, Mass., Nov. 25, 2013 /PRNewswire/ — Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) ha…
Arzerra Gets a New Boxed Warning – Legal Examiner
Arzerra Gets a New Boxed WarningLegal ExaminerThe anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) recently got an upgrade to their boxed warning labels, adding information about the potential risk for reactivation of hepatitis B infectio…
Creating synthetic antibodies – R & D Magazine
R & D Magazine |
Creating synthetic antibodies
R & D Magazine To create these “synthetic antibodies,” the researchers used carbon nanotubes—hollow, nanometer-thick cylinders made of carbon that naturally fluoresce when exposed to laser light. In the past, researchers have exploited this phenomenon to create … Team Creates ‘Synthetic Antibodies‘Bioscience Technology Synthetic antibodies work in new sensortce today |
Launceston duo clock up 100th blood donation – Tasmania Examiner
|
Launceston duo clock up 100th blood donation
Tasmania Examiner She said each blood donation could save up to three lives. Mr Hogarth and Mr Ling have been giving blood for more than 25 years. “So if you look at their donations they’ve potentially saved 300 lives each,” she said. “They really are making a … |
UPA Chairperson Felicitates India's First Successful Liver Transplant … – Moneylife
|
UPA Chairperson Felicitates India’s First Successful Liver Transplant …
Moneylife UPA Chairperson and Congress Party President, Smt. Sonia Gandhi today felicitated India’s first successful liver transplant recipient, Sanjay Kandasamy from Kancheepuram, Tamil Nadu who had undergone a liver transplant in November 1998 at Apollo … |
UPA Chairperson Felicitates India's First Successful Liver Transplant … – PR Newswire India (press release)
|
UPA Chairperson Felicitates India’s First Successful Liver Transplant …
PR Newswire India (press release) UPA Chairperson and Congress Party President, Smt. Sonia Gandhi today felicitated India’s first successful liver transplant recipient, Sanjay Kandasamy from Kancheepuram, Tamil Nadu who had undergone a liver transplant in November 1998 at Apollo … |
Engineers synthesize antibodies with carbon nanotubes – Phys.Org
|
Engineers synthesize antibodies with carbon nanotubes
Phys.Org To create these “synthetic antibodies,” the researchers used carbon nanotubes—hollow, nanometer-thick cylinders made of carbon that naturally fluoresce when exposed to laser light. In the past, researchers have exploited this phenomenon to create … |
US group opposes Gilead's patenting of hepatitis C drug in India – domain-B
Hindu Business Line |
US group opposes Gilead’s patenting of hepatitis C drug in India
domain-B US drug-maker Gilead Sciences’ patent application on hepatitis C drug sofosbuvir in India is facing opposition from a US legal group I-MAK (Initiative for Medicines, Access & Knowledge) on the ground that it is old known compound and has nothing new to … US group seeks to block Gilead drug patent in IndiaEconomic Times US group against Gilead’s patent request in India for hepatitis C drugTopNews United States Indian health activists move to prevent Gilead’s drug patentFinancial Times |